Benefits to Attending

Transcription

1 Day 1 Enabling Technologies For Peptide Screening, Synthesis And Modification Promising methods to extend half-life peptide capabilities Activating synthesis technologies: HLPC, mass spectrometry, microwave-assisted SPPS Enhancing peptide stability through PEGylation, cyclization and amino acid incorporation Updates in peptide self-assembly & macromolecular assembly Advances in research involving high affinity binding peptides Novel peptide applications for intracellular targets New approaches for high-throughput screening Day 2 Peptide Case Studies: Discovery, Preclinical And Clinical Development, Therapeutic Applications, Peptide Formulation And Delivery Updates in preclinical discovery and clinical development Innovative therapeutic applications for peptides Latest advances and future perspectives in peptide delivery Cell-penetrating peptides: opportunities, challenges and future directions New strategies utilizing routes of administration for peptide formulation Peptidomimetics: enhancing drugability and bioavailability Recent developments: macrocyclic, polypeptides and bioactive peptides Benefits to Attending Hear from and meet with the key innovators involved in peptide chemistry, discovery, preclinical and clinical development, delivery and formulation. Previous attendees include: VP Peptides, CMC & Engineering, Ipsen; VP Medicinal Chemistry, Pfizer; VP Peptide Chemistry, Novo Nordisk. Discover collaborative solutions to peptides challenges. This congress brings together peptide experts to discuss the promising methods to extend half-life peptide capabilities, new approaches for high-throughput screening and novel synthesis technologies. Discuss the latest innovations in peptide development. Case studies include updates in peptide discovery, new therapeutic applications, peptidomimetics and latest advances and future perspectives in peptide delivery. Unparalleled networking opportunities. The two-day congress format combines dedicated networking breaks, 1-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion. A high quality programme devised with the help of our esteemed advisory board. Presentations will cover areas including peptide libraries, carrier protein selection and conjugation chemistry, macrocyclic, polypeptides and cellpenetrating peptides. Co-located with the 8 th Annual Proteins & Antibodies Congress and 3 rd Annual Biosimilars & Biobetters Congress Speakers Include Michael Wagner Christophe Bonny Paul Feldman Sanofi-Aventis Bicycle Therapeutics GlaxoSmithKline Meet Senior Decision Makers 200 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include: Peptide Chemistry Peptide Development R&D Technologies Peptide Synthesis Peptide Formulation Biologics Research Therapeutic Peptides Peptide Discovery Peptidomimetics Molecular Biology Peptide Delivery Peptide Characterisation Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include: Peptide Libraries Peptide Screening Peptide Mapping Peptide Modification Peptide Design Peptide Conjugation Peptide Coupling Peptide Array Stability Technologies Peptide Purification Custom Peptide Synthesis Peptide Columns Date & Location: The 2 nd Annual Peptides Congress will take place at Novotel London West hotel on April, Confirmed S

2 Confirmed Speakers 2015: Joel Richard, Senior Vice President, Peptides Head of CMCS Dreux Site, Ipsen Paul Feldman, Senior Vice President, GlaxoSmithKline Alastair Lawson, Research Fellow & VP Structural Biology, UCB Lutz Jermutus, Senior Director, R&D, MedImmune Alireza Manuchehri, Director, Clinical Development, Eisai Ltd Tomas Landh, Director, Strategy and Innovation Sourcing Diabetes Research Unit, Novo Nordisk Lyn Jones, Head of Rare Diseases Chemistry, Head of Chemical Biology, Pfizer Michael Wagner, Director Medicinal Chemistry, Head of Peptides, Sanofi-Aventis Graham Simpson, CPU Head, Peptides Chemistry, GlaxoSmithKline Konrad Bleicher, Peptide Area Head Discovery Chemistry, pred, Roche Innovation Centre Basel Fabio Fais, Principal Scientist, Formulation Project Leader, Novartis Pharma AG Daniel Kirchhofer, Principal Scientist, Early Discovery Biochemistry, Genentech Daniel Yin, Principal Scientist, Parenteral Formulation Sciences, Merck Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Ltd Torsten Hoffmann, Executive Vice President and Chief Scientific Officer, Zealand Pharma Gert Moll, CSO, Lanthio Pharma Dinesh Patel, President & CEO, Protagonist Therapeutics Aphrodite Kapurniotu, Professor for Peptide Biochemistry, Technische Universität München Scientific Advisory Board: Spiros Liras, VP CVMED Medical Chemistry, Pfizer Joel Richard, Senior Vice President, Peptides Head of CMCE Dreux Site, Ipsen Jesper Lau, Vice President Protein & Peptide Chemistry, Novo Nordisk A/S Ronald Swanson, Senior Director, Biologics Research, Janssen R&D Michael Shapiro, Director of Analytical Chemistry, Pfizer Chris Herring, Director, Head of Protein Sciences, GlaxoSmithKline Thomas Vorherr, Director Peptide Discovery, Novartis Graham Simpson, CPU Head, Peptides Chemistry, GlaxoSmithKline Janos Kodra, Principal Scientist, Novo Nordisk A/S Stefan Geschwindner, Principal Scientist Biophysics, AstraZeneca R&D Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Ltd Volker Schellenberger, President and CEO, Amunix Operating Inc Chantal Alcouffe, Medicinal Chemist Group Leader, Sanofi Fernando Albericio, Group Leader, Institute for Research in Biomedicine-Barcelona (IRB), University of Barcelona Confirmed Sponsors 2015: 2014 Delegate Testimonials: The talks addressed the most recent approaches in the peptide field, and the networking drinks were a great bonus. Director of Chemistry, Ipsen The talks were very interesting and I appreciated having the opportunity to meet other scientists. We were able to present our antibody technology via posters, and the solution providers were relevant to my work. Research Scientist, UCB This Congress provided a good overview of the biosimilars industry, from different experts in different domains. It was also interesting to see how the business around biosimilars is evolving. Process Co-Ordinator Manufacturing, Merck Serono

3 Registration Oxford Global s Welcome Address Chairperson s Opening Address Co-located Keynote Address: To be confirmed 2 nd Annual Peptides Congress Day One 20 th April 2015 Enabling Technologies For Peptide Screening, Synthesis And Modification Keynote Address: Antibodies As Tools In Small Molecule Drug Discovery The dynamics of target proteins sampling different conformations Function-modifying antibodies defining biologically-relevant conformations New opportunities for allosteric modulation Alastair Lawson, Research Fellow & VP Structural Biology, UCB Solution Provider Presentation Coffee & Refreshments One to One Meetings x3 Poster Presentation Sessions Case Study On Peptide Research And Development At MedImmune Lutz Jermutus, Senior Director, R&D, MedImmune Protein Labeling Using Sulfonyl Fluorides Applications To Drug Discovery This talk will describe the use of sulfonyl fluoride probes to augment the medicinal chemistry and chemical biology toolbox. Sulfonyl fluoride functionality is privileged in that they modify context-specific serine, tyrosine, lysine, histidine and cysteine residues. We have recently harnessed this reactivity to target reactive tyrosine residues in a protein binding site (that of the decapping scavenger enzyme DcpS) for the first time. This led to the development of a method to quantify target engagement in-cell that more accurately assesses physiologically-relevant pharmacology. Lyn Jones, Head of Rare Diseases Chemistry, Head of Chemical Biology, Pfizer Solution Provider Presentation Lunch Stabilized Peptides As Therapeutics: Opportunities And Challenges Features of intracellular cyclic peptide inhibitors Novel approaches to improving their druggability Graham Simpson, CPU Head, Peptides Chemistry, GlaxoSmithKline New Opportunities In Peptide Design: De Novo, Sequencing From Native Proteins Daniel Yin, Principal Scientist, Parenteral Formulation Sciences, Merck Solution Provider Presentation Afternoon Refreshments One to One Meetings x 2 Poster Presentation Sessions

4 2 nd Annual Peptides Congress Day One 20 th April Bi-Cyclic Peptides Drug Conjugates The Bicycle technology is based on repertoires of peptides displayed on the surface of bacteriophages which can be modified with organochemical scaffolds to create a diverse array of constrained peptides. These repertoires have been extensively used for iterative selections to identify high affinity binding peptides for a wide array of targets, including receptors, interleukins and proteases. The bicycle peptides show antibody-like properties such as low to sub-nanomolar affinities and exquisite selectivity, but in a 100-fold smaller, chemically synthesized format. Due to their small size, these small entities extravasate and penetrate tumours much more efficiently than antibodies. Bicycle Therapeutics will present results from its pre-clinical programs addressing 4 different oncology targets to deliver cytotoxic payloads to tumour cells. Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Networking Drinks End of Day One

5 Conference Room: Stream Chair: 2 nd Annual Peptides Congress Day Two 21 st April 2015 Peptide Case Studies: Discovery, Preclinical And Clinical Development, Therapeutic Applications, Peptide Formulation And Delivery Keynote Address: Oral Peptide Delivery: How To Address The Challenges Of Stability In The GI Tract And Oral Bioavailability Expected benefits of oral peptides versus injectable sustained-release formulations Formulating peptides to enhance oral bioavailability Discussing the pros and cons of the oral peptide technologies in regards to: o Stability o Bioavailability o Safety and efficacy o Impact on CoGs and manufacturability Case studies: Examining clinical results and models for oral peptides in development o Oral pharmacokinetics versus subcutaneous injection o Food effects o Targeting receptors in the GI tract Joel Richard, Senior Vice President, Peptides Head of CMCE Dreux Site, Ipsen Enteroendocrine Peptide Drug Discovery For Treatment Of Metabolic Diseases Paul Feldman, Senior Vice President, GlaxoSmithKline Solution Provider Presentation Morning Coffee & Poster Presentations One to One Meetings x2 Poster Presentation Sessions Safety Aspect Of Clinical Trials With Peptides/Immunologicals And The Risk Of PML Alireza Manuchehri, Director, Clinical Development, Eisai Case Study: Peptide Formulation & Delivery At Novo Nordisk Tomas Landh, Director, Strategy and Innovation Sourcing Diabetes Research Unit, Novo Nordisk Solution Provider Presentation Lunch Designed Polypharmacology: From Dual To Triple And Back With the introduction of different epitopes, peptides can be designed to trigger various pharmaceutical pathways. Here we disclose some of our activities in the Incretin field where highly potent entities were discovered. Efforts to increase the duration of action will also be addressed. Konrad Bleicher, Peptide Area Head Discovery Chemistry, pred, Roche Innovation Centre Basel Recent Progress In Peptide Sustained Release Approaches For The Treatment Of Diabetes & Obesity Michael Wagner, Director Medicinal Chemistry, Head of Peptides, Sanofi-Aventis Review On Advanced Drug Delivery Technologies For Peptides Fabio Fais, Principal Scientist, Formulation Project Leader, Novartis Pharma AG Afternoon Refreshments

6 2 nd Annual Peptides Congress Day Two 21 st April Engineering Peptide Inhibitors Of PCSK9 For LDL Cholesterol Lowering Proprotein convertase subtilisin/kexin type 9 (PCSK9) circulates in blood and is a negative regulator of liver LDL receptors. Therapeutic inhibition of PCSK9 by monoclonal antibodies shows remarkable reductions of LDL cholesterol levels in ongoing clinical trials. Development of small molecule inhibitors is hampered by the challenging nature of the target PCSK9. We used established phage display technologies to generate structured peptides that inhibit PCSK9 function, such as affinity-improved variants of the LDL-receptor EGF(A) domain, which neutralized PCSK9 in-vitro and in-vivo. In a different phage display approach, we were able to obtain a small 13 amino acid peptide, which completely inhibits LDL receptor binding and displays partial structural mimicry of the EGF(A) domain. The results demonstrate the feasibility of developing peptidic inhibitors to functionally relevant sites on PCSK9. Daniel Kirchhofer, Principal Scientist, Early Discovery Biochemistry, Genentech Peptide Therapeutics - Current Status And Future Directions At Zealand Pharma ( Zealand ) we invent, design, synthetize, and develop peptide-based therapeutics as potential new medicines. Peptides are recognized for being highly selective and efficacious and at the same time relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical R&D and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. As the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell-penetrating peptides as well as peptide drug conjugates. Here, we discuss the current status, the strengths and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development. Torsten Hoffmann, Executive Vice President and Chief Scientific Officer, Zealand Pharma Lanthionine-Stabilized Peptides With Enhanced Target Selectivity Enzymatic introduction of lanthionines into peptides and bacterial production of lanthipeptides Bacterial cell surface display of lanthipeptides Preclinical development of LP2, a lanthipeptide agonist of the angiotensin II type 2 receptor Gert Moll, CSO, Lanthio Pharma Case Study On Protagonist Therapeutics Peptides Clinical Program Dinesh Patel, President & CEO, Protagonist Therapeutics Designed Peptides As Potent Inhibitors Of Protein Aggregation And Cell Degeneration In Alzheimer's Disease And Type II Diabetes Designed synthetic peptides Inhibitors of protein aggregation Amyloid formation and cell degeneration in AD/T2D Therapeutic leads in AD / T2D Aphrodite Kapurniotu, Professor for Peptide Biochemistry, Technische Universität München End of Conference

7 2nd Annual Peptides Congress th and 21st April 2015, London, UK HOW TO REGISTER Please complete your personal and payment details in the space provided below and return the form via fax on :- +44 (0) Delegate Details Registration Fees Please complete fully and clearly. Please photocopy for additional delegates Standard Price (VAT is charged at 20%) Title: Forename: Surname: Job Title: Company/Organisation: Address: Industry delegates (Biopharma, Pharma or Biotech Companies) Academic delegates Vendor delegates (CROs, Consultants, Technology and Service Providers) VAT VAT VAT Postcode: Country: Direct Telephone Direct Fax: Mobile: Switchboard: Signature: Date: How to Pay (choose one of the following payment options) Number of delegates: Industry del(s) Academic dels(s) Vendor dels(s) CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number: Valid from: / Expiry Date: / Security code: Cardholders name: Signature: Date: PLEASE INVOICE ME: Invoice ADDRESS (if different from above) *Please note there is a 50 + VAT handling charge for payment via invoice. *Payment by credit card is subject to 3% bank charge or 4% AMEX. Special Offer Terms & Conditions Agreed Terms between the Organiser (Oxford Global) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of 50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, , telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/ her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. I agree to the above Terms and Conditions 3 for 2 Offer REGISTER ONLINE: or contact marketing@oxfordglobal.co.uk or call +44 (0)